Cover Image
市場調查報告書

ephrin-A受體2:開發中產品分析

Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 365774
出版日期 內容資訊 英文 52 Pages
訂單完成後即時交付
價格
Back to Top
ephrin-A受體2:開發中產品分析 Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Pipeline Review, H1 2016
出版日期: 2016年06月30日 內容資訊: 英文 52 Pages
簡介

本報告提供以ephrin-A受體2為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,再加上企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

ephrin-A受體2 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Bristol-Myers Squibb Company
  • 第一三共
  • Galapagos NV
  • Merrimack Pharmaceuticals, Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0229TDB

Summary

Global Markets Direct's, 'Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Pipeline Review, H1 2016', provides in depth analysis on Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1)
  • The report reviews Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) Overview
  • Therapeutics Development
    • Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Products under Development by Stage of Development
    • Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Products under Development by Therapy Area
    • Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Products under Development by Indication
  • Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Products under Development by Companies
  • Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Products under Development by Universities/Institutes
  • Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
    • Bristol-Myers Squibb Company
    • Daiichi Sankyo Company, Limited
    • Galapagos NV
    • Merrimack Pharmaceuticals, Inc.
  • Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Drug Profiles
    • Antisense RNAi Oligonucleotide to Inhibit EPHA2 for Solid Tumor and Ovarian Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dasatinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DS-8895 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GLPG-1790 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MM-310 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Activate EPHA2 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Dormant Projects
  • Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Discontinued Products
  • Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Featured News & Press Releases
    • Jun 09, 2016: Bristol-Myers Squibb to Present Data on Sprycel (dasatinib) at the 21st Congress of the European Hematology Association
    • Apr 21, 2016: Merrimack Unveils its Latest Antibody Directed Nanotherapeutic, MM-310, at the 2016 AACR Annual Meeting
    • Mar 16, 2016: Merrimack to Present on MM-310 at the 2016 American Association for Cancer Research Annual Meeting
    • Aug 13, 2015: FDA Approves U.S. Product Labeling Update for Sprycel (dasatinib) to Include Five-Year First-Line and Seven-Year Second-Line Efficacy and Safety Data in Chronic Myeloid Leukemia in Chronic Phase
    • Jul 06, 2015: Delhi High Court Upholds BMS' Patent For Dasatinib
    • Jun 29, 2015: Mayo Clinic study suggests which glioblastoma patients may benefit from drug treatment
    • Nov 07, 2014: Bristol-Myers Squibb Announces Oral Presentations of Sprycel at 56th Annual American Society for Hematology (ASH) Meeting
    • Oct 19, 2014: DIPP Seeks Information On Dasatinib For Issuance Of Compulsory Licences
    • May 07, 2014: India Seeks Waiver Of Bristol-Myers Squibb's Patent Rights For Dasatinib
    • Mar 18, 2014: Galapagos to present favorable pre-clinical data on GLPG1790, a selective ephrin receptor kinase inhibitor, at AACR in San Diego
    • Dec 09, 2013: Four-Year Data from Phase 3 DASISION Trial Comparing Sprycel (dasatinib) to Imatinib in First-Line Treatment of Adults with Ph+ CP-CML Presented at Annual Meeting of the American Society of Hematology
    • Jun 20, 2013: Bristol-Myers And Otsuka Announce FDA Approval For US Product Labeling Update For Sprycel
    • Apr 22, 2013: Galapagos Discovers New Drug Candidate To Treat Breast Cancer
    • Mar 20, 2013: Moffitt Cancer Center Researchers Study Use of Dasatinib for Patients with High-Risk MDS
    • Mar 19, 2013: BDR Pharma Applies For Compulsory License To Sell Generic Version Of Bristol-Myers Squibb's Cancer Drug Dasatanib In India
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Pipeline by Galapagos NV, H1 2016
  • Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016
  • Dormant Projects, H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top